• MHH spin-off Cardior will be taken over for up to EUR 1.025 billion including an upfront payment and additional payments if certain development and commercial milestones are achieved.
• Cardior has pioneered a new approach for the treatment of heart disease by targeting distinctive non-coding RNAs.
• Cardior’s Phase II candidate CDR132L is supported by strong Phase I and preclinical data suggesting the compound is safe and able to achieve cardiac functional improvements.
   

dentalXrai and Tube Pharmaceuticals were both acquired by international key players in their respective fields. The transactions add new momentum, development and marketing power to the start-ups’ projects.

Biomax Informatics AG, a well-established start-up from the Helmholtz Zentrum München, has been acquired by Horizonte Venture Management. The proceeds from the sale of Ascenion’s equity will be distributed as research grants via the LifeScience Foundation.

The NUVISAN group, an international service provider for clinical studies, contract development and manufacturing (CRO/CDMO) with headquarters in…

New drug delivery system to enable needle-free application of drugs

Simultaneously Closes Strategic Growth Investment from Ampersand Capital to Create a Leading Provider of Genomic and Cell and Tissue Analysis Products…

Boost for the first new tuberculosis vaccine in nearly 100 years 

21 August 2018, Munich – Ascenion GmbH, the technology transfer partner of the…

Making cancer surgery more precise

23 October 2017, Munich – SurgVision BV, a spin-off from the Helmholtz Zentrum München, has been acquired by…